UBS Initiates Coverage of Iovance Biotherapeutics (LSE:0JDK) with Buy Recommendation

Fintel reports that on October 24, 2024, UBS initiated coverage of Iovance Biotherapeutics (LSE:0JDK) with a Buy recommendation. https://www.nasdaq.com/articles/ubs-initiates-coverage-iovance-biotherapeutics-lse-0jdk-buy-recommendation